Generic Dilaudid-HP Availability
Last updated on Apr 10, 2025.
See also: Generic Dilaudid
Dilaudid-HP is a brand name of hydromorphone, approved by the FDA in the following formulation(s):
DILAUDID-HP (hydromorphone hydrochloride - injectable;injection)
-
Manufacturer: FRESENIUS KABI USA
Approval date: January 11, 1984
Strength(s): 10MG/ML (discontinued) [RLD] -
Manufacturer: FRESENIUS KABI USA
Approval date: August 4, 1994
Strength(s): 250MG/VIAL (discontinued)
All of the above formulations have been discontinued.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Dilaudid-HP. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Packaging system for oxygen-sensitive drugs
Patent 9,248,229
Issued: February 2, 2016
Inventor(s): Devouassoux Thomas & Forat Eric & Proctor James Kenneth
Assignee(s): Becton, Dickinson France S.A.S.Described herein are pharmaceutical packaging systems which prevent oxidative degradation of morphine, hydromorphone, promethazine and other oxygen-sensitive drugs, such systems including a syringe with an oxygen permeable tip cap, a hermetically sealed oxygen barrier blister packaging with very low permeability to oxygen and comprises ethylene vinyl, and an oxygen absorber.
Patent expiration dates:
- March 12, 2034✓
- March 12, 2034
-
Drug container
Patent 9,731,082
Issued: August 15, 2017
Inventor(s): Vernizeau Michel & Foucher Cedric & Lefebvre Lionel
Assignee(s): Fresenius Kabi Deutschland GmbHThe present invention relates to an assembly () comprising: an injection device () comprising a container () for a product, said container comprising a distal tip (), an adaptor () comprising a ring () mounted onto said distal tip (), characterized in that said assembly () further comprises a heat-shrinkable film () covering part () of said container () and part () of said adaptor (), said film () maintaining said adaptor () blocked in rotation and in translation with respect to said container () when said film () is in its heat-shrunk condition. The invention further relates to a method for manufacturing such an assembly.
Patent expiration dates:
- April 23, 2032✓
- April 23, 2032
More about Dilaudid-HP (hydromorphone)
- Dilaudid-HP consumer information
- Check interactions
- Compare alternatives
- Reviews (9)
- Latest FDA alerts (11)
- Side effects
- Dosage information
- During pregnancy
- Drug class: Opioids (narcotic analgesics)
- Breastfeeding
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.